Pharmacological characterization of PABSA, an orally active and highly potent endothelin-receptor antagonist

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 1, 1999, Pages 139-147

  Iwasaki, Takanori ^a   Mihara, Shin Ichi ^a   Shimamura, Toshitake ^a   Kawakami, Masaru ^a   Hayasaki Kajiwara, Yoko ^a   Naya, Noriyuki ^a   Fujimoto, Masafumi ^a   Nakajima, Masatoshi ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

Endothelin receptor antagonist; Hypotensive effect; Oral bioavailability; PABSA; Rats

Indexed keywords

2 [BENZO(1,3)DIOXOL 5 YL] N (4 ISOPROPYLPHENYLSULFONYL) 2 (6 METHYL 2 PROPYLPYRIDIN 3 YLOXY)ACETAMIDE; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; TAK 044; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; RAT; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

ADMINISTRATION, ORAL; ANIMALS; AORTA; BINDING, COMPETITIVE; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE; CELLS, CULTURED; DESOXYCORTICOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENDOTHELINS; MALE; MUSCLE, SMOOTH, VASCULAR; RABBITS; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, ENDOTHELIN; SUCCINATES; TIME FACTORS; VASOCONSTRICTION; VASODILATION;

EID: 0033026336     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199907000-00022     Document Type: Article

References (45)

1. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989;86:2863-7.
2. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
3. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994;46:325-415.
4. De Nucci G, Thomas R, D'Orléans-Juste P, et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Nad Acad Sci USA 1988;85:9797-800.
5. Battistini B, Chailler P, D'Orléans-Juste P, Briere N, Sirois P. Growth regulatory properties of endothelins. Peptides 1993;14: 385-99.
6. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990;348:730-2.
7. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990;348:732-5.
8. Warner TD, Allcock GH, Corder R, Vane JR. Use of the endothelin antagonists BQ-123 and PD142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. Br J Pharmacol 1993;110:777-82.
9. B receptors mediating venous smooth muscle contraction. Biochem Biophys Res Commun 1994; 200:627-33.
10. Miyauchi T, Yorikane R, Sakai S, et al. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 1993;73:887-97.
11. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996;384:353-5.
12. A receptor antagonist, FR139317, ameliorates cerebral vasospasm in dogs. Life Sci 1993;52:1869-74.
13. A receptor. Life Sci 1991;50:247-55.
14. B receptors. J Pharmacol Exp Ther 1996;279:675-85.
15. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan: a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994;270:228-35.
16. Ohlstein EH, Beck GR, Douglas SA, et al. Nonpeptide endothelin receptor antagonists: II. pharmacological characterization of SB209670. J Pharmacol Exp Ther 1994;271:762-8.
17. A receptor-specific effect of 50-235: a nonpeptide endothelin antagonist. Eur J Pharmacol 1993;246:33-8.
18. Elshourbagy NA, Lee JA, Korman DR, et al. Molecular cloning and characterization of the major endothelin receptor subtype in porcine cerebellum. J Pharmacol Exp Ther 1992;41:465-73.
19. 50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-108.
20. Caplan BA, Gerrity RG, Schwartz CJ. Endothelial cell morphology in focal areas of in vivo Evans Blue uptake in the young pig aorta: I. Quantitative light microscopic findings. Exp Mol Pathol 1974; 21:102-17.
21. Matsuda S, Kurokawa K, Higuchi K, Imamura N, Hakata H, Ueda M. A new blood pressure measuring apparatus equipped with a microcomputer system for conscious rats. J Pharmacol Methods 1987;17:361-76.
22. A receptor antagonist. J Pharmacol Exp Ther 1995;273:1410-7.
23. Williams DL, Murphy KL, Nolan NA, et al. Pharmacology of L-754,142, a highly potent, orally active, nonpeptidyl endothelin antagonist. J Pharmacol Exp Ther 1995;275:1518-26.
24. A-selective receptor antagonist. J Pharmacol Exp Ther 1996; 276:473-81.
25. A receptor antagonist. J Pharmacol Exp Ther 1998;286:650-6.
26. Hoshino T, Yamauchi R, Kikkawa K, Yabana H, Murata S. Pharmacological profile of T-0201: a highly potent and orally active endothelin receptor antagonist. J Pharmacol Exp Ther 1998;286: 643-9.
27. Rhaleb NE, Rouissi N, Nantel F, D'Orléans-Juste P, Regoli D. Dup753 is a specific antagonist for the angiotensin receptor. Hypertension 1991;17:480-4.
28. Burns L, Clark KL, Bradley J, Clark AJL. Molecular cloning of the canine angiotensin II receptor. FEBS Lett 1994;343:146-50.
29. Robertson MJ, Dougall IG, Harper D, McKechnie KCW, Leff P. Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model. Trends Pharmacol Sci 1994; 15:364-9.
30. B receptor in spontaneously hypertensive and Wistar-Kyoto rats. Eur J Pharmacol 1996;296:55-63.
31. A receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension. Br J Pharmacol 1995;114:925-30.
32. Nishikibe M, Tsuchida S, Okada M, et al. Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci 1993;52:717-24.
33. Bolger GT, Liard F, Krogsrud R, Thibeault D, Jaramillo J. Tissue specificity of endothelin binding sites. J Cardiovasc Pharmacol 1990;16:367-75.
34. McMahon EG, Palomo MA, Brown MA, Bertenshaw SR, Carter JS. Effect of phosphoramidon (endothelin converting enzyme inhibitor) and BQ-123 (endothelin receptor subtype A antagonist) on blood pressure in hypertensive rats. Am J Hypertens 1993;6:667-73.
35. Bird JE, Moreland S, Waldron TL, Powell JR. Antihypertensive effects of a novel endothelin-A receptor antagonist in rats. Hypertension 1995;25:1191-5.
36. A antagonist on structure and function of small arteries from stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 1998;31(suppl 1): S309-12.
37. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994;344:852-4.
38. Haynes WG, Ferro CJ, O'Kane KPJ, Somerville D, Lomax CC, Webb DJ. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996;93:1860-70.
39. Letizia C, Cerci S, De Toma G, et al. High plasma endothelin-1 levels in hypertensive patients with low-renin essential hypertension. J Hum Hypertens 1997;11:447-51.
40. Ferri C, Bellini C, Desideri G, Mazzocchi C, De Siati L, Santucci A. Elevated plasma and urinary endothelin-1 levels in human salt-sensitive hypertension. Clin Sci 1997;93:35-41.
41. Miyauchi T, Yanagisawa M, Tomizawa T, et al. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet 1989;ii:53-4.
42. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure. Circulation 1992;85:1374-9.
43. Suzuki R, Masaoka H, Hirata Y, Marumo F, Isotani E, Hirakawa K. The role of endothelin-1 in the origin of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 1992;77:96-100.
44. Dagassan PH, Breu V, Clozel M, et al. Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol 1996;27:147-53.
45. B receptor-mediated contraction in human pulmonary resistance arteries. Br J Pharmacol 1996;119:1125-30.